Home > Journals > Minerva Urologica e Nefrologica > Past Issues > Minerva Urologica e Nefrologica 2012 December;64(4) > Minerva Urologica e Nefrologica 2012 December;64(4):225-31

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

MINERVA UROLOGICA E NEFROLOGICA

A Journal on Nephrology and Urology


Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,984


eTOC

 

  ADVANCES IN ONCOLOGICAL UROLOGY


Minerva Urologica e Nefrologica 2012 December;64(4):225-31

Copyright © 2013 EDIZIONI MINERVA MEDICA

language: English

Prevention strategies for prostate cancer

Schmitz-Dräger B. J. 1, Lümmen G. 2, Bismarck E. 1, Fischer C. 3

1 EuromedClinic, Fürth, Germany; 2 Department of Urology, St. Josef Hospital Troisdorf, Germany; 3 Clinic of Urology, Klinikum Hohe Warte Bayreuth, Germany


PDF  


Through the last decade consideration of the role of vitamins and minerals in primary prevention of genitourinary tumors has dramatically changed. Despite all efforts efficacy of a specific compound has not been proven, so far. In consequence, recommendations for a use of vitamins or other supplements with the intention of prostate cancer prevention should be avoided today. In contrast, there is some evidence that life style modification might be helpful: recent investigations suggest that smoking may be involved in prostate cancer carcinogenesis. In addition, there is evidence that moderate food consumption, reduction of dairy products and an Asian or Mediterranean diet might not only prevent prostate cancer but also harbors additional beneficial effects on general health. This move from single compounds to more complex diets can be considered as a change of paradigm in prostate cancer prevention and could be the starting point of future epidemiological research. Disappointing findings with regards to nutritional cancer prevention contrast with a solid evidence concerning the efficacy of chemoprevention using 5a-reductase inhibitors: Long-term use of Finasteride and Dutasteride significantly reduces prostate cancer detection. Further candidate drugs are under investigation. However, translation of these findings into urological practice remains a matter of controversial discussion.

top of page

Publication History

Cite this article as

Corresponding author e-mail

bernd-sd@yahoo.de